Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TEM
stocks logo

TEM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast TEM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEM is 89.36 USD with a low forecast of 80.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast TEM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEM is 89.36 USD with a low forecast of 80.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
6 Hold
0 Sell
Moderate Buy
Current: 66.050
sliders
Low
80.00
Averages
89.36
High
100.00
Current: 66.050
sliders
Low
80.00
Averages
89.36
High
100.00
Morgan Stanley
NULL -> Overweight
upgrade
$68 -> $80
2025-11-11
Reason
Morgan Stanley
Price Target
$68 -> $80
2025-11-11
upgrade
NULL -> Overweight
Reason
Morgan Stanley raised the firm's price target on Tempus AI to $80 from $68 and keeps an Overweight rating on the shares.
Piper Sandler
Neutral
downgrade
$105 -> $80
2025-11-11
Reason
Piper Sandler
Price Target
$105 -> $80
2025-11-11
downgrade
Neutral
Reason
Piper Sandler lowered the firm's price target on Tempus AI to $80 from $105 and keeps a Neutral rating on the shares. The firm cites the company's quarterly results for the price target change.
H.C. Wainwright
Yi Chen
Buy
downgrade
$98 -> $89
2025-11-07
Reason
H.C. Wainwright
Yi Chen
Price Target
$98 -> $89
2025-11-07
downgrade
Buy
Reason
H.C. Wainwright analyst Yi Chen lowered the firm's price target on Tempus AI to $89 from $98 and keeps a Buy rating on the shares post the Q3 report. The firm expects Tempus AI's sales growth in 2026 "to be healthy" at above 20%, but significantly less than the rate in 2025.
Canaccord
Kyle Mikson
Buy
downgrade
$110 -> $95
2025-11-05
Reason
Canaccord
Kyle Mikson
Price Target
$110 -> $95
2025-11-05
downgrade
Buy
Reason
Canaccord analyst Kyle Mikson lowered the firm's price target on Tempus AI to $95 from $110 and keeps a Buy rating on the shares. The firm said its target decrease is driven by lower revenue growth and operating margin expansion in the out years of their 10-year DCF model and noted the he company's Q3 performance was driven by solid execution across each of its business segments.
Piper Sandler
Overweight
maintain
$60 -> $90
2025-10-22
Reason
Piper Sandler
Price Target
$60 -> $90
2025-10-22
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Guardant Health to $90 from $60 and keeps an Overweight rating on the shares. The firm surveyed 59 oncologists to gauge their views on profiling and market share. Overall, Piper thinks the survey is positive for companies such as Guardant Health (GH) and Tempus AI (TEM). The firm sees liquid biopsy, where it believes Guardant has a first-mover advantage, as growing even faster than CGP, and saw significant interest in it among different use cases.
Piper Sandler
Neutral
maintain
$70 -> $105
2025-10-22
Reason
Piper Sandler
Price Target
$70 -> $105
2025-10-22
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on Tempus AI to $105 from $70 and keeps a Neutral rating on the shares. The firm surveyed 59 oncologists to gauge their views on profiling and market share. Overall, Piper thinks the survey is positive for companies such as Guardant Health (GH) and Tempus AI (TEM). The firm sees liquid biopsy as growing even faster than CGP, and saw significant interest in it among different use cases.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Tempus AI Inc (TEM.O) is -345.34, compared to its 5-year average forward P/E of -96.04. For a more detailed relative valuation and DCF analysis to assess Tempus AI Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-96.04
Current PE
-345.34
Overvalued PE
-32.24
Undervalued PE
-159.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
48.69
Current EV/EBITDA
368.77
Overvalued EV/EBITDA
1695.05
Undervalued EV/EBITDA
-1597.67

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
11.20
Current PS
68.48
Overvalued PS
24.80
Undervalued PS
-2.39
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 884.13% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

TEM News & Events

Events Timeline

(ET)
2025-11-04
16:04:33
Tempus AI Adjusts 2025 Sales Forecast to $1.265B, Aligning with Consensus of $1.26B
select
2025-11-04
16:03:55
Tempus AI Announces Q3 Earnings Per Share of 11 Cents, Below Consensus Estimate of 18 Cents
select
2025-10-16 (ET)
2025-10-16
08:32:24
Tempus AI partners with Whitehawk Therapeutics to enhance cancer research
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-18NASDAQ.COM
Tempus AI Falls into Oversold Zone (TEM)

  • Current Trading Status: Tempus AI Inc (TEM) shares have entered oversold territory with an RSI of 29.6, trading as low as $65.53 per share, compared to the S&P 500 ETF's RSI of 40.5.

  • Investor Perspective: The low RSI reading may indicate that heavy selling is nearing exhaustion, potentially presenting buying opportunities for bullish investors.

  • 52-Week Performance: TEM's 52-week low is $31.36 and the high is $104.32, with the last trade recorded at $66.39.

  • Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.

[object Object]
Preview
9.5
11-17NASDAQ.COM
What Factors Contributed to Tempus AI Achieving Positive EBITDA in Q3?

  • Tempus AI Financial Performance: Tempus AI reported a positive adjusted EBITDA of $1.5 million in Q3, driven by strong growth in its Genomics and Data Licensing businesses, with significant increases in Oncology and Hereditary testing volumes.

  • Myriad Genetics and Quest Diagnostics: Myriad Genetics achieved an adjusted EBITDA of $10.3 million, supported by a high gross margin and controlled expenses, while Quest Diagnostics improved profitability with expanded margins and ongoing cost-saving initiatives.

  • Stock Performance and Market Position: Tempus AI's shares have increased by 26.7% over the past year, outperforming industry and S&P 500 averages, and the company's stock currently has a forward Price-to-Sales ratio of 8.00X, above the industry average.

  • Emerging Quantum Computing Trends: Quantum computing is rapidly advancing, with major tech companies integrating it into their infrastructure, and investment strategist Kevin Cook identifies key stocks that may lead in this emerging field.

[object Object]
Preview
7.5
11-14Newsfilter
Tempus and IFLI Launch Research Initiative to Enhance Understanding of Follicular Lymphoma

  • Collaboration Announcement: Tempus AI, Inc. has launched its first study in collaboration with the Institute for Follicular Lymphoma Innovation (IFLI) to create a comprehensive dataset for follicular lymphoma (FL) patients, aiming to enhance precision medicine and biomarker discovery.

  • Study Objectives: The multi-year study will utilize advanced technologies such as next-generation sequencing and proteomics to generate a robust, multi-omic dataset, which will support the development of innovative therapies and improve patient outcomes in FL.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Tempus AI Inc (TEM) stock price today?

The current price of TEM is 66.05 USD — it has decreased -0.51 % in the last trading day.

arrow icon

What is Tempus AI Inc (TEM)'s business?

Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.

arrow icon

What is the price predicton of TEM Stock?

Wall Street analysts forecast TEM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEM is 89.36 USD with a low forecast of 80.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Tempus AI Inc (TEM)'s revenue for the last quarter?

Tempus AI Inc revenue for the last quarter amounts to 334.21M USD, increased 84.72 % YoY.

arrow icon

What is Tempus AI Inc (TEM)'s earnings per share (EPS) for the last quarter?

Tempus AI Inc. EPS for the last quarter amounts to -0.46 USD, decreased -0.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Tempus AI Inc (TEM)'s fundamentals?

The market is revising Upward the revenue expectations for Tempus AI, Inc. (TEM) for FY2025, with the revenue forecasts being adjusted by 0.41% over the past three months. During the same period, the stock price has changed by -15.81%.
arrow icon

How many employees does Tempus AI Inc (TEM). have?

Tempus AI Inc (TEM) has 2400 emplpoyees as of November 19 2025.

arrow icon

What is Tempus AI Inc (TEM) market cap?

Today TEM has the market capitalization of 11.81B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto Tracker
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free